\
&
Contact us
This was 3 months ago
LocationLyngby, Denmark
The Technical University of Denmark (DTU) in collaboration with the Danish Presidency of the Council of the European Union organises a High-Level Conference to explore how academia can attract and retain the brightest minds and shape the future of research in Europe. Are European universities ready to meet the aspirations of early-career researchers?
Bringing together more than 200 people, and attracting the most relevant stakeholders, such as early career researchers, policymakers, university leaders, industry representatives, and other socio-economic actors, the conference will create a space for interactive discussions on the purpose-driven university, working culture, and intersectoral mobility.
Registration will open for onsite and online participation in April 2025. More information about the registration, conference programme, MSCA Falling Walls Lab Pitch competition, testimonials from 10 researchers from Danish universities and practical details is available on the website of the conference.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.